Patterns of Tumor Infiltrating Lymphocytes in Adenoid Cystic Carcinoma of the Head and Neck.
adenoid cystic carcinoma
head and neck
tertiary lymphoid structures
tumor-infiltrating lymphocytes
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
08 Mar 2022
08 Mar 2022
Historique:
received:
01
02
2022
revised:
23
02
2022
accepted:
05
03
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
26
3
2022
Statut:
epublish
Résumé
Adenoid cystic carcinoma (ACC) is a rare malignancy in the head and neck. The prognosis remains poor and late recurrences often occur after 5 years and later. To date, there are no reliable prognostic markers for ACC. In several solid tumors, tertiary lymphoid structures (TLS) are associated with improved survival. This study aims to investigate the role of distribution patterns of tumor infiltrating immune cells (TIL) in ACC. A cohort of 50 patients from three different cancer centers was available for analysis. Sections were stained for CD3, CD4, CD8 and CD20 and evaluated with regard to their distribution of TIL. Patterns were determined as infiltrated-excluded, infiltrated-inflamed and presence of tertiary lymphoid structures. About half of the cases showed an infiltrated-excluded TIL pattern and only a minority of six cases had TLS present within the tumor. Within the inflamed phenotype CD3+ cells were by far the most abundant lymphocyte subtype, and within this compartment, CD8+ T cells were predominant. There was no influence on overall or disease-free survival by any of the TIL patterns. This indicates that ACC is a tumor with very low immunogenicity and even abundance of lymphocytes does not seem to improve prognosis for this disease. Therefore, the observed lack of response towards immunotherapy is not surprising and other methods to induce recognition of ACC by the immune system must be found.
Identifiants
pubmed: 35326536
pii: cancers14061383
doi: 10.3390/cancers14061383
pmc: PMC8946094
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : 451445144
Références
Am J Clin Oncol. 2011 Feb;34(1):76-81
pubmed: 20177363
Am J Surg. 1974 Oct;128(4):512-20
pubmed: 4371368
J Exp Med. 2019 Sep 2;216(9):2128-2149
pubmed: 31227543
Front Immunol. 2021 Mar 08;12:626776
pubmed: 33763071
Hum Pathol. 2017 Nov;69:110-117
pubmed: 28993275
Pathologe. 2018 Nov;39(6):532-538
pubmed: 30350175
Clin Cancer Res. 2020 Jun 15;26(12):2859-2870
pubmed: 32060100
Onco Targets Ther. 2017 Jun 13;10:2983-2992
pubmed: 28652780
Am J Cancer Res. 2021 Sep 15;11(9):4092-4110
pubmed: 34659878
Immunol Rev. 2016 May;271(1):260-75
pubmed: 27088920
Cancer Immunol Res. 2016 Aug;4(8):679-87
pubmed: 27312343
Cancer Manag Res. 2021 Mar 15;13:2411-2417
pubmed: 33758540
Front Oncol. 2020 Nov 11;10:593379
pubmed: 33262950
Nat Immunol. 2017 Aug;18(8):940-950
pubmed: 28628092
Oral Oncol. 2019 Mar;90:30-37
pubmed: 30846173
Int J Radiat Oncol Biol Phys. 2021 Jan 1;109(1):134-144
pubmed: 32781104
Clin Invest Med. 2021 Mar 21;44(1):E38-41
pubmed: 33743575
BMC Bioinformatics. 2014 Aug 29;15:293
pubmed: 25176396
J Immunother Cancer. 2021 Jun;9(6):
pubmed: 34103353
Oral Oncol. 2021 Apr;115:105213
pubmed: 33578204
J Immunol. 2018 Jan 15;200(2):432-442
pubmed: 29311385
Oral Oncol. 2019 Jan;88:95-101
pubmed: 30616805
Front Immunol. 2017 Dec 19;8:1830
pubmed: 29312327
Nat Commun. 2021 Jun 7;12(1):3349
pubmed: 34099645
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
Acta Otolaryngol. 2018 Jan;138(1):73-79
pubmed: 28899226
Nat Rev Immunol. 2021 Jul 12;:
pubmed: 34253904
Cell Mol Immunol. 2020 Jun;17(6):570-575
pubmed: 32415259
Front Mol Biosci. 2021 Sep 08;8:661516
pubmed: 34568423
Am J Clin Oncol. 2018 Nov;41(11):1083-1088
pubmed: 29462123